Opko健康 OPK 深 沪
等待开盘 08-25 09:30:00 美东时间
1.485
+0.005
+0.34%
华盛通- 最 高1.51
- 今 开1.49
- 成交量 87.65万股
- 最 低 1.4725
- 昨 收 1.48
- 总市值 11.08亿
- 52周最高 1.73
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 0.9769
- 委 比 76.25%
- 总股本 7.46亿
- 历史最高 19.20
- 量 比 0.87
- 振 幅 2.53%
- 历史最低 0.8516
- 每 手 1
- 风险率 0.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Opko Health Expands Royalty-Backed Long-Term Note Financing
Opko Health ( ($OPK) ) has shared an update. On August 13, 2026, OPKO Health am...
08-15 05:19
OPKO Health Issues Additional $125M Of Senior Secured Notes To KKR's HealthCare Royalty For Non-Dilutive Funding
The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement. The transaction provides OPKO with a...
08-13 21:20
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
OPKO Health expanded its financing with HealthCare Royalty, issuing an additional $125 million in senior secured notes. These notes are backed by mazdutide royalties and mature in 2044. The transaction provides non-dilutive capital while preserving long-term royalty upside. OPKO retains future royalty economics after capped payments of 1.5 times the funded amount. Mazdutide is commercialized in China by Innovent Biologics, with OPKO receiving roy...
08-13 13:15
Entera Q2 2026 earnings: Phase 3 preparation widened the loss
Entera Bio’s Q2 2026 earnings showed no revenue and a net loss of $7.3 million, versus $2.7 million a year earlier, while loss per share widened to $0.14 from $0.06. R&D expense rose to $3.2 million as the company prepared EB613 for a planned late-2026 Phase 3 start and advanced work under its OPKO collaboration. After quarter-end, Entera completed a $275 million private placement that it expects will fund the EB613 registrational program through
08-07 20:18
Entera Announces Second Quarter 2026 Financial Results and Business Updates
Entera Bio Ltd. reported financial results and updates for Q2 2026, highlighting FDA alignment on a 12-month Phase 3 study for EB613, an oral anabolic tablet for postmenopausal osteoporosis. The company secured $275M in private placement led by BVF Partners to fund EB613's development through NDA submission. EB613's Phase 3 initiation is planned for late 2026, with topline data expected in H2 2028. Additionally, preclinical data for EB612, an ora...
08-07 20:05
OPKO Health Boosts Stake in Cocrystal Pharma Financing
Cocrystal Pharma ( ($COCP) ) has shared an announcement. On August 3, 2026, Coc...
08-03 19:48
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
Cocrystal Pharma announced a $5 million investment from long-term investor OPKO Health to advance its lead norovirus program toward Phase 1b data expected late in 2026. OPKO acquired 5,474,053 shares at $0.9134 per share. Both companies expressed confidence in Cocrystal's science and pipeline, which includes treatments for influenza, coronaviruses, and hepatitis C.
08-03 11:00
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Entera Bio Ltd. CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The event will be held in Boston and available via webcast. Entera, a leader in oral peptide development, is advancing innovative therapies for osteoporosis, hypoparathyroidism, obesity, and rare conditions.
07-31 20:30
美股牛股 | AI基建股IOND首日升近26%，为21年来最大直接上市项目；Lucid劲升21%
AI基建股IOND首日升近26%，为21年来最大直接上市项目；医药股PMN飙升23%，阿尔茨海默病药物试验结果积极；Lucid劲升21%，获沙特首富1.3亿美元投资>>
07-29 19:00
Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of Celestica Inc (NYSE:CLS) rose sharply in pre-market trading after the company posted its second-quarter results, beating analyst estimates on the top and bottom lines. Celestica reported quarterly earnings of $2.54 per share, which beat the Street estimate of $2.30 by 10.43%, according to ...
07-28 17:01
